Sandoz is the generic and biosimilar division of Novartis Group
Our History
In 1996 Sandoz and Ciba-Geigy were merged. This merger led to the creation of Novartis and Sandoz brand became dormant for a few years. In 2003, when Novartis united its global generics businesses under a single global brand, the name Sandoz was reestablished.
Irit Starobin
[email protected]
תוצרת הארץ 6, תל אביב, P.O.B. 7126
0545211409
Our Representatives
Our purpose
At Sandoz, we discover new ways to improve and extend people’s lives. We pioneer novel approaches to help people around the world access high-quality medicine. To achieve this, we pursue an integrated access strategy that focuses our work on improving access to medicines, access to medical information and access to medical capacity building, which includes efforts to provide and support appropriate training for healthcare professionals. In 2019, our products reached well over 500 million patients worldwide.
To read more about Sandoz history please visit: www.sandoz.com/about-us/who-we-are/sandoz-brand
Erelzi Physician Prescribing Information
Hyrimoz Physician Prescribing Information